Cytek Biosciences, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-ramp DCF: $206.7M TTM revenue growing 12%/year; FCF margin ramping linearly from -6% today to +18% by year 10 as the flow-cytometry instrument/consumables business scales; 11% discount rate; 4% terminal growth; plus $235.54M net cash. Equity value ≈ $1,000M / 129.98M shares = $7.70/share.

Reasoning: Cytek is a high-growth, high-gross-margin life-sciences tools company that is currently unprofitable while scaling; a margin-ramp DCF captures the path to profitability better than a flat-FCF model, and the large net cash position (32% of market cap) is added back explicitly rather than embedded in a terminal multiple.